June 13 2017 Issue

06/12/17 • 21 min

Show description/summary:1) Evaluating the safety of beta-interferons in multiple sclerosis 2) Neurology® Today: New Classifications of Seizures and Epilepsies Include New Seizure Types, Simpler TermsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 13, 2017 issue of Neurology. In the first segment, Dr. Michael Levy talks with Dr. Helen Tremlett and Dr. Hilda De Jong about their paper on evaluating the safety of beta-interferons in multiple sclerosis. In the next part of the podcast Dr. Nathan Fountain focuses his interview with Dr. Robert Fisher on the new classifications of seizures and epilepsies presented by the International League Against Epilepsy. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Levy serves on advisory boards for Asterias, Chugai, and Alexion; serves as Editorial Board member of Multiple Sclerosis and Related Disorders; holds patents for an aquaporin-4 sequence that elicits pathogenic T cell response in animal model of neuromyelitis optica, and for use of a peptide for diagnostic and therapeutic developments; has consulted for Guidepoint Global, Gerson Lehrman Group, and Cowen Group; and has received research support from Viropharma/Shire, Acorda, ApoPharma and Sanofi, Genzyme, Alnylam, Alexion, Terumo BCT, National Institute of Neurological Diseases and Stroke, and Guthy-Jackson Charitable Foundation.Dr. Tremlett has served on scientific advisory boards for US National MS Society and the Centers for Disease Control and Prevention; is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis; has received research support from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, Canada Foundation for Innovation, the Multiple Sclerosis Society of Canada, US National Multiple Sclerosis Society, Multiple Sclerosis Scientific Research Foundation, Michael Smith Foundation for Health Research, and the UK MS Trust; has received speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres, the National MS Society, ECTRIMS, the Chesapeake Health Education Program, US Veterans Affairs, Novartis Canada, Biogen Idec, American Academy of Neurology.Dr. Fountain is an epileptologist at the University of Virginia Comprehensive Epilepsy Program (100% effort).All other participants report no disclosures.

Previous Episode

Practice Current: Antiepileptic Drug Discontinuation

Delayed Recall - June 2017In this special Delayed Recall episode, Dr. Luca Bartolini speaks with epilepsy experts Dr. Greg Cascino, Dr. Ali Asadi-Pooya, and Dr. Ley Sander. They discuss the results of a recent Practice Current (a section of Neurology® Clinical Practice) survey regarding antiepileptic drug discontinuation, and share their thoughts on best practices with regard to the case studies presented to the survey respondents. This is the first appearance of this interview in the podcast.

Next Episode

Delayed Recall - Neuro-oncology Lessons of the Week (July 2017)

In this month's Delayed Recall episode, we are featuring four interviews by Dr. Kait Nevel on the topic of neuro-oncology. In the first interview, Dr. Nevel speaks with Dr. Jennie Taylor about neuro-oncology and seizures. In the second, she discusses intracranial pressure with Dr. Mariza Daras. These interviews originally appeared in the March 7 and March 14 episodes, respectively. Next, Dr. Nevel and Dr. Lisa DeAngelis talk about metastatic diseases in neurology, in a segment that appeared in the March 21 episode. Last, Dr. Nevel discusses gliomas with Dr. David Schiff in an interview from March 28.